

ISA-PLENARY session

PLENARY SESSIONS 1. HEART DISEASE: FROM CRADLE TO CORONARY CARE UNIT

Chairpersons: Virgil Brown – Atlanta, USA / Phil Barter – Sydney, Australia

08:30	08:30 – 09:00	Epidemiology of CVD ●	Kay Tee Khaw – Cambridge, UK
	09:00 – 09:30	CV Risk & Early Intervention ●	John Deanfield – London, UK
	09:30 – 10:00	Genetics: Use in Causality CVD ●●	Sekar Kathiresan – Boston, USA
10:30	10:00 – 10:30	LDL Lowering Therapies ●●	Evan Stein – Chicago, USA

RAPID FIRE ARENA

09:00	09:00 – 10:30	RAPID FIRE SESSION 1: Atherosclerosis ●
10:30	09:00 – 10:30	RAPID FIRE SESSION 2: Cardiovascular Disease ●

POSTER area

POSTER SESSIONS 1

09:00	09:00 – 13:15	Atherosclerosis ●
	09:00 – 13:15	Innovation in animal models / Human disease – human models ●
	09:00 – 13:15	Lipids, lipoproteins & inflammation ●
	13:15	09:00 – 13:15

CLINICAL BREAKTHROUGHS IN ATHEROSCLEROSIS

11:45 – 13:00	CLINICAL BREAKTHROUGHS SESSION 1: A Plethora of new therapeutic targets ●●
---------------	----------------------------------------------------------------------------

X-CHANGE session

XCHANGE SESSION 1 ●

EPIDEMIOLOGY OF CVD AND CURRENT RISK STRATIFICATION

Chairpersons: Eran Leitersdorf – Jerusalem, Israel / Naveed Sattar – Glasgow, UK

XCHANGE SESSION 2 ●

PATHOGENESIS OF ATHEROSCLEROSIS

Chairpersons: Yasufumi Sato – Sendai, Japan / Rob de Winter – Amsterdam, The Netherlands

11:00	11:00-11:25	From Framingham to EPIC-Norfolk: Risk factors in perspective (1948 – 2015) Kay Tee Khaw – Cambridge, UK	11:00 – 11:20	The inflammatory process as the driver behind the unstable patient and the ruptured plaque: What are the interventions? Esther Lutgens – Amsterdam, The Netherlands
	11:25 – 11:45	One pill for all or different strategies for different patients: Personalized Epidemiology today Frank Visseren – Utrecht, The Netherlands	11:20 – 11:40	Atherogenesis and plaque vulnerability: Where endothelium and angiogenesis meet Paul Quax – Leiden, The Netherlands
	11:45 – 12:10	High-dose or low-dose statin, with ezetimibe or without ezetimibe: Where do we go from here in secondary prevention? Colin Baigent – Oxford, UK	11:40 – 12:10	In which animal models of atherosclerosis can interventions be translated to human therapy? Kylie Kavanagh – Winston-Salem, USA
	12:10 – 12:20	ABSTRACT 315 Peter Würtz – Helsinki, Finland	12:10 – 12:20	ABSTRACT 552 Judith Sluimer – Maastricht, The Netherlands
	12:20 – 12:30	ABSTRACT 317 Peter Würtz – Helsinki, Finland	12:20 – 12:30	ABSTRACT 628 Marit Westerterp – New York, USA
	12:30 – 12:40	ABSTRACT 483 Ko Willems van Dijk – Leiden, The Netherlands	12:30 – 12:40	ABSTRACT 692 Peter Meikle – Melbourne, Australia
	12:40 – 12:45	DISCUSSION	12:40 – 12:45	DISCUSSION

XCHANGE SESSION 3 ●●

NOVEL INTERVENTIONS IN BLOOD PRESSURE MANAGEMENT

Chairpersons: Wiek van Gilst – Groningen, The Netherlands / Thomas MacDonald – Dundee, UK

XCHANGE SESSION 4 ●

NOVEL ORAL ANTICOAGULANTS

Chairpersons: Ron Peters – Amsterdam, The Netherlands / Gregory Lip – Birmingham, UK

12:45	11:00 – 11:20	Resistant Hypertension: Fact or fiction? Wilko Spiering – Utrecht, The Netherlands	11:00 – 11:35	The role of Novel Oral Anticoagulants in the management of atrial fibrillation Gregory Lip – Birmingham, UK
	11:20 – 11:45	Ambulatory and central blood pressure measurement: What is their value in management of essential hypertension? Thomas MacDonald – Dundee, UK	11:35 – 12:10	What is the position of NOACs in acute coronary syndromes & secondary prevention? Ron Peters – Amsterdam, The Netherlands
	11:45 – 12:10	Variability in blood pressure readings: Impact on CV outcome and consequences for therapy Peter Rothwell – Oxford, UK		
	12:10 – 12:30	Genetics of essential hypertension: Any new targets on the horizon? Eric Sijbrands – Rotterdam, The Netherlands	12:10 – 12:45	Deep Vein Thrombosis: Diagnostics and management in the latest state-of-the-art Harry Büller – Amsterdam, The Netherlands
	12:30 – 12:40	ABSTRACT 406 Jonica Campolo – Milan, Italy		
	12:40 – 12:45	DISCUSSION		

11:00 – 12:45	CHINESE SATELLITE SYMPOSIUM 1: Metabolic Cardiovascular Diseases: Translational Research on dyslipidemia, diabetes and atherosclerosis
---------------	----------------------------------------------------------------------------------------------------------------------------------------

11:00 – 14:00	SCREENPRO FH
---------------	--------------

I-POSTER area **MODERATED POSTERS SESSION 1**

12:30	12:30 – 14:30	Atherosclerosis	●
	12:30 – 14:30	Disrupting genes and pathways: Tell me more about it	●
14:30	12:30 – 14:30	Lipids, lipoproteins and emerging risk factors	●

INDUSTRY SPONSORED SYMPOSIUM

13:15	13:15 – 14:15	AMGEN	Transforming patient care in Familial Hypercholesterolaemia: The potential role of global registries and PCSK9 inhibition
	13:15 – 14:15	Lilly	Managing dyslipidaemia – where do we go? Clinical cases from daily practice
14:15	13:15 – 14:15	Kowa	Clinical considerations focusing on lipid modification and metabolic risk / risk factors

POSTER area **POSTERS SESSION 2**

09:00 – 13:15	Diabetes & CVD	●
09:00 – 13:15	Endothelium and VSMCs: The first passage	●
09:00 – 13:15	Cardiovascular disease & Vascular risk factors	●
09:00 – 13:15	Diabetes & Blood	●

X-CHANGE session

XCHANGE SESSION 5 ● ●

DIABETES AND ITS NOVEL INTERVENTIONS

Chairpersons: Max Nieuwdorp – Amsterdam, The Netherlands / Jane Armitage – Oxford, UK

14:45	14:45 – 15:10	Novel antidiabetic drugs: The story of the trees and the forest; has their position crystallized? Nikolaus Marx – Aachen, Germany
	15:10 – 15:35	Sugar versus fat: Is treatment of dyslipidemia relevant for diabetics? Naveed Sattar – Glasgow, UK
	15:35 – 16:00	Sugar versus pressure: How important is blood pressure control in diabetics? Thomas MacDonald – Dundee, UK
	16:00 – 16:10	Abstract 554 Maaike Schilperoort – Leiden, The Netherlands
	16:10 – 16:20	Abstract 754 Giuseppe Derosa – Pavia, Italy
	16:20 – 16:30	Abstract 823 John Chapman – Paris, France

XCHANGE SESSION 6 ●

PCSK9: FROM BIOLOGY TO THERAPY

Chairpersons: Gilles Lambert – Nantes, France / Meral Kayıkçıoğlu – Izmir, Turkey

14:45 – 15:10	The biology of PCSK9 in humans: Just LDL-cholesterol or more? Gilles Lambert – Nantes, France
15:10 – 15:40	Genetic variation at the PCSK9 locus: A contributor to CV risk? Jean-Claude Tardif – Montréal, Canada
15:40 – 16:05	The latest intervention in ACS: The monoclonal antibody against PCSK9 Henry Ginsberg – New York, USA
16:05 – 16:30	The PCSK9 protein: A key modulator of cardiovascular outcome Nabil Seidah – Montreal, Canada

XCHANGE SESSION 7 ●

IMAGING & ATHEROSCLEROSIS

Chairpersons: Jacqueline de Graaf – Nijmegen, The Netherlands / Ahmed Tawakol – Boston, USA

16:30	14:45-15:15	Intracoronary grayscale IVUS leads the way: For how long? Steve Nissen – Cleveland, USA
	15:15-15:45	Non-invasive imaging of the myocardium and the coronaries: Ready for prime time? Zahi Fayad – New York, USA
	15:45-16:10	Inflamed atherosclerosis: The clinical relevance of PET-CT James Rudd – Cambridge, UK
	16:10-16:30	In-vivo imaging and the patho-physiology of human atherosclerosis Erik Stroes – Amsterdam, The Netherlands

XCHANGE SESSION 8 ●

INFLAMMATION, THE IMMUNE SYSTEM & ATHEROSCLEROSIS

Chairpersons: Lale Tokgozozglu – Ankara, Turkey / Peter Libby – Boston, USA

14:45 – 15:05	Trained immunity and human atherogenesis; consequences for treatment? Mihai Netea – Nijmegen, The Netherlands
15:05 – 15:25	Immunology, inflammation and cardiovascular disease Jon Laman – Groningen, The Netherlands
15:25 – 15:50	The pro-inflammatory state as a risk factor for atherogenesis Wolfgang Koenig – Ulm, Germany
15:50 – 16:20	How to intervene in the pro-inflammatory state? Clinical studies in humans Paul Ridker – Boston, USA
16:20 – 16:30	Abstract 134 Iize Bot – Leiden, The Netherlands

14:45 – 16:30 **SPANISH SATELLITE SYMPOSIUM: Clinical and genetic challenges in the Diagnosis and Management of FH**

ISA-PLENARY session

PLENARY SESSION 2. CONTROVERSIES IN HEART DISEASE AND NUTRITION: ARE WE WHAT WE EAT?

Chairpersons: John Kastelein – Amsterdam, The Netherlands / Naveed Sattar – Glasgow, UK

17:00	17:00 – 17:30	Obesity and CVD: it is not what you think it is! ● ●	Jean-Pierre Després – Québec, Canada
	17:30 – 18:00	Nutrition and CVD: Ten Steps Forward, Nine Steps Back ● ●	Martijn Katan – Amsterdam, The Netherlands

RAPID FIRE ARENA

17:00	17:00 – 18:00	RAPID FIRE SESSION 3: Dyslipidemia / genetics 1	●
18:00	17:00 – 18:00	RAPID FIRE SESSION 4: Non coding RNAs: Finding the treasure in the junk	●

INDUSTRY SPONSORED SYMPOSIUM

18:30 – 20:00	SANOPI REGENERON	The LDL-C hypothesis – yesterday, today and tomorrow
---------------	------------------	------------------------------------------------------

MONDAY, MAY 25, 2015 / 1

ISA-PLENARY sessions

PLENARY SESSION 3. FAT AND DISEASE: IS IT ALL ABOUT TRIGLYCERIDES?

Chairpersons: Jean-Pierre Després – Québec, Canada / Christie Ballantyne – Houston, USA

08:30	08:30 - 09:00	Triglyceridemia as Risk Factor for CVD	● ●	Robert Hegele – London, Ontario, Canada
	09:00 – 09:30	Central Role of ApoC3	● ●	Ann Tybjaerg-Hansen – Copenhagen, Denmark
	09:30 – 10:00	Fibrates and Nicotinic Acid: Where did it all go wrong?	● ●	Phil Barter – Sydney, Australia
10:30	10:00 – 10:30	Therapy of Hypertriglyceridemia: What does the future hold?	● ●	Michael Davidson – Chicago, USA

RAPID FIRE ARENA

09:00	09:00 – 10:30	RAPID FIRE SESSION 5: Diabetes, metabolic disease and atherosclerosis	●
10:30	09:00 – 10:30	RAPID FIRE SESSION 6: Atherosclerosis	●

POSTER area

POSTERS SESSION 3

09:00 – 13:15	Dyslipidemia / genetics	●
09:00 – 13:15	Inflammatory response: The origin of vascular pathology	●
09:00 – 13:15	Dyslipidemia / genetics	●
09:00 – 13:15	Atherosclerosis	●

CLINICAL BREAKTHROUGHS IN ATHEROSCLEROSIS

12:00-13:00	CLINICAL BREAKTHROUGHS SESSION 2: Lowering triglycerides as the next target in CV disease	● ●
-------------	-------------------------------------------------------------------------------------------	-----

X-CHANGE session

XCHANGE SESSION 9
OBESITY & VISCERAL FAT

Chairpersons: Esther Lutgens – Amsterdam, The Netherlands / Jean-Pierre Després – Québec, Canada

XCHANGE SESSION 10
SINGLE GENE DISORDERS OF LIPOPROTEIN METABOLISM

Chairpersons: Robert Hegele – London, Ontario, Canada / Eric Sijbrands – Rotterdam, The Netherlands

11:00	11:00 – 11:30	State of the art: The contribution of visceral fat and adiponectin to cardiovascular risk Yuji Matsuzawa – Osaka, Japan	11:00 – 11:30	Human syndromes associated with very low and very high triglyceride levels Geesje Dallinga-Thie – Amsterdam, The Netherlands
	11:30 – 11:50	Brown adipose tissue: A novel target to combat cardiovascular disease? Patrick Rensen – Leiden, The Netherlands	11:30 – 12:00	Dysbetalipoproteinaemia: A disease of remnants and high CV risk David Marais – Cape Town, South Africa
	11:50 – 12:10	The role of the intestinal microbiota in the inflammation of visceral fat Max Nieuwdorp – Amsterdam, The Netherlands	12:00 – 12:20	The high-TG, low-HDL syndrome: Very prevalent but not well understood Jan Albert Kuivenhoven – Groningen, The Netherlands
	12:10 – 12:35	How effective is bariatric surgery at the short and long term? Rachel Batterham – London, UK	12:20 – 12:30	ABSTRACT 604 Nabil Seidah – Montreal, Canada
	12:35 – 12:45	ABSTRACT 825 Kjetil Retterstøl – Oslo, Norway	12:30 – 12:40	ABSTRACT 756 Erik Stroes – Amsterdam, The Netherlands
12:45			12:40 – 12:45	DISCUSSION

X-CHANGE session

XCHANGE SESSION 11
REVERSE CHOLESTEROL TRANSPORT

Chairpersons: Attilio Rigotti – Santiago, Chile / Miranda van Eck – Leiden, The Netherlands

11:00	11:00 – 11:25	Cholesterol efflux, immune function and atherosclerosis Alan Tall – New York, USA
	11:25 – 11:45	How to get rid of cholesterol: Non-HDL mediated reverse cholesterol transport Bert Groen – Groningen, The Netherlands
	11:45 – 12:10	Apo-A1 mimetic peptides; small molecules with large effects: Can they be the next ACS therapy? Alan Remaley – Bethesda, USA
	12:10 – 12:35	Probuco: A novel function for an old molecule in reverse cholesterol transport Shizuya Yamashita – Osaka, Japan
	12:35 – 12:45	Abstract 601 Giulia Sara Ganzetti – Milan, Italy

XCHANGE SESSION 12
NEW INSIGHTS INTO HYPOLIPIDAEMIC DRUGS

Chairpersons: Andrey Susekov – Moscow, Russia / Sam Tsimikas – La Jolla, USA

11:00	11:00 – 11:25	Statins forever and nicotinic acid in the waste-bin? Data from clinical studies Jane Armitage – Oxford, UK
	11:25 – 11:50	MTP inhibition for hoFH and chylomicronemia? Mariko Harada-Shiba – Tokyo, Japan
	11:50 – 12:05	mRNA inhibition of ApoB synthesis: An alternative to LDL-receptor upregulation? John Kastelein – Amsterdam, The Netherlands
	12:05 – 12:35	The resurrection of ezetimibe: A story of perseverance Harry Davis – Rahway, USA
	12:35 – 12:45	Abstract 372 Tom Seijkens – Amsterdam, The Netherlands

11:00 – 12:45 CCEP / IAS JOINT SYMPOSIUM: The lipid management of the high risk patient

I-POSTER area **MODERATED POSTERS SESSION 2**

12:30	12:30 – 14:30	Dyslipidemia / genetics	●
	12:30 – 14:30	The inflammatory cell: The jack of all traits	●
14:30	12:30 – 14:30	Atherosclerosis & Cardiovascular disease	●

INDUSTRY SPONSORED SYMPOSIUM

13:15	13:15 – 14:15	Engineering the future for those at high cardiovascular risk
	13:15 – 14:15	Why reducing LDL-Cholesterol matters: An evidence-based discussion
14:15	13:15 – 14:15	Cardiovascular inflammation and immunity in atherosclerosis: Clinical Perspectives

POSTER area **POSTERS SESSION 4**

13:15	13:15 – 18:00	HDL	●
	13:15 – 18:00	Biomarkers; imaging of vascular disease	●
	13:15 – 18:00	Obesity & Lifestyle	●
	13:15 – 18:00	Nutrition	●

X-CHANGE session

XCHANGE SESSION 13
FAMILIAL HYPERCHOLESTEROLEMIA

Chairpersons: Raul Santos – Sao Paulo, Brazil / Katherine Wilemon – South Pasadena, USA

14:45	14:45 – 15:15	Homozygous FH: From a lethal disorder to a manageable dyslipidemia Frederick Raal – Johannesburg, South Africa
	15:15 – 15:35	Heterozygous FH: Amazingly prevalent and astonishingly diverse Kees Hovingh – Amsterdam, The Netherlands
	15:35 – 16:05	We need to diagnose heterozygous FH in childhood: The why and how Samuel Gidding – Wilmington/Philadelphia, USA
	16:05 – 16:15	ABSTRACT 672 Masahiro Koseki – Osaka, Japan
	16:15 – 16:25	ABSTRACT 881 Guy De Backer – Ghent, Belgium
	16:25 – 16:30	DISCUSSION

XCHANGE SESSION 14
NOVEL INSIGHTS INTO LP(A)

Chairpersons: Bülent Behlül Altunkeser – Konya, Turkey / Richard Češka – Prague, Czech Republic

14:45	14:45 – 15:10	The epidemiology of Lp(a) in the general population and in those with CAD Pia Kamstrup – Copenhagen, Denmark
	15:10 – 15:35	New insights into Lipoprotein(a) biology and contributions to vascular disease Marlys Koschinsky – Windsor, Ontario, Canada
	15:35 – 16:05	How are we going to intervene in elevated Lp(a)? From PCSK9 to mRNA inhibition Sam Tsimikas – La Jolla, USA
	16:05 – 16:30	Specific Lipoprotein(a) apheresis for coronary and carotid atherosclerosis regression in stable ischemic heart disease patients Sergei Pokrovsky – Moscow, Russia

X-CHANGE session

XCHANGE SESSION 15 ●
HDL FUNCTIONALITY

Chairpersons: Jan Albert Kuivenhoven – Groningen, The Netherlands / Ruth Frikke Schmidt – Copenhagen, Denmark

14:45	14:45 – 15:15	The composition and atheroprotective function of the HDL particle: Latest insights Kerry-Anne Rye – Sydney, Australia / Jan Albert Kuivenhoven – Groningen, The Netherlands
	15:15 – 15:40	Why does the HDL particle give up during an acute coronary syndrome: The dysfunctional HDL syndrome Ulf Landmesser – Berlin, Germany
	15:40 – 16:05	The endothelium as a target and a barrier for HDL (dys)function Arnold von Eckardstein – Zürich, Switzerland
16:30	16:05 – 16:30	Lipoprotein changes after HDL infusion: Do they translate into improved functionality? Cesare Sirtori – Milan, Italy

XCHANGE SESSION 16 ●●
TRIGLYCERIDE-RICH LIPOPROTEINS

Chairpersons: Daniel Gaudet – Montreal, Canada / Manuel Castro Cabezas – Rotterdam, The Netherlands

14:45	14:45 – 15:10	Human syndromes characterized by extreme hypertriglyceridemia: From LPL to ApoC2 and back again Daniel Gaudet – Montréal, Canada
	15:10 – 15:40	Are triglyceride-rich lipoproteins involved in atherogenesis? Genetics, epidemiology and biology tell the story Robert Hegele – London, Ontario, Canada
	15:40 – 16:10	There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Christie Ballantyne – Houston, USA
	16:10 – 16:20	ABSTRACT 720 Blake Cochran – Sydney, Australia
	16:20 – 16:30	ABSTRACT 784 Richard Lee – Carlsbad, USA

14:45 – 16:30 **RUSSIAN SATELLITE SYMPOSIUM 1: Statin therapy at the crossroad of the decade: What we know and what we would like to know**

ISA-PLENARY session ● **PLENARY SESSION 4. THE HDL CONTROVERSY: IS THE PARTICLE IRRELEVANT FOR ATHEROGENESIS?**
Chairpersons: Antonio Gotto – New York, USA / Erik Stroes – Amsterdam, The Netherlands

17:00	17:00 - 17:30	Biological Function of HDL ●	Ulf Landmesser – Zürich, Switzerland
18:00	17:30 - 18:00	HDL Plays No Role in the Pathogenesis of Atherosclerosis ●	Børge Nordestgaard – Copenhagen, Denmark

RAPID FIRE ARENA ●

17:00	17:00 – 18:00	RAPID FIRE SESSION 7: Lipids, diabetes and vascular risk ●
18:00	17:00 – 18:00	RAPID FIRE SESSION 8: Nutrition ●

TUESDAY, MAY 26, 2015 / 1

ISA-PLENARY sessions ● **PLENARY SESSION 5. INFLAMMATION, THE IMMUNE SYSTEM AND HEART DISEASE: PROOF?**
Chairpersons: Mihai Netea – Nijmegen, The Netherlands / Matthias Nahrendorf – Boston, USA

08:30	08:30 – 09:00	Innate immunity in atherosclerosis: cause or companion? ●	Peter Libby – Boston, USA
	09:00 – 09:30	Adaptive immunity, the Janus of atherosclerosis ●	Göran Hansson – Stockholm, Sweden
	09:30 – 10:00	Inflammation & Imaging ●	Ahmed Tawakol – Boston, USA
10:30	10:00 – 10:30	Immunomodulation Therapy for Atherosclerosis ●	Jan Nilsson – Lund, Sweden

FH CONNECT

08:30 – 10:30 **FH-CONNECT** ●●

RAPID FIRE ARENA ●

09:00	09:00 – 10:30	RAPID FIRE SESSION 9: Therapy ●
10:30	09:00 – 10:30	RAPID FIRE SESSION 10: Vascular risk factors and risk estimation ●

POSTER area ● **POSTERS SESSION 5**

09:00	09:00 – 13:15	FH ●
	09:00 – 13:15	Intervention in lipid pathways; Lipid metabolism: Mechanisms and interventions ●
	09:00 – 13:15	Risk factors and risk stratification ●
13:15	09:00 – 13:15	Cardiovascular disease ●

CLINICAL BREAKTHROUGHS IN ATHEROSCLEROSIS ●

11:30 – 13:00 **CLINICAL BREAKTHROUGHS SESSION 3: Modifying LDL cholesterol to prevent CV events** ●●

X-CHANGE session

XCHANGE SESSION 17
THE VULNERABLE PLAQUE

Chairpersons: Allard van der Wal – Amsterdam, The Netherlands / Ira Tabas – New York, USA

11:00	11:00 – 11:20	The vulnerable atherosclerotic plaque; the evidence in mice compared to humans: Time for a resetting of targets? Gerard Pasterkamp – Utrecht, The Netherlands
	11:20 – 11:40	The most recent insights into vulnerable plaque imaging in humans with CAD Ton van der Steen – Rotterdam, The Netherlands
	11:40 – 12:10	How to fight the fire: Therapies to reduce inflammation and rupture of vulnerable plaques Stephen Nicholls – Adelaide, Australia
	12:10 – 12:20	ABSTRACT 148 Nikki Dieleman – Utrecht, The Netherlands
	12:20 – 12:30	ABSTRACT 562 Anton Gisterå – Stockholm, Sweden
	12:30 – 12:40	ABSTRACT 670 Jun Pu – Shanghai, China
	12:40 – 12:45	DISCUSSION

XCHANGE SESSION 18
HDL THERAPIES

Chairpersons: Frank Visseren – Utrecht, The Netherlands / Phil Barter – Sydney, Australia

	11:00 – 11:25	HDL-like particle infusion to promote cholesterol efflux from macrophages and stimulate RCT in humans Daniel Rader – Philadelphia, USA
	11:25 – 11:55	Delipidation and reinfusion of native HDL: How a machine might be the future of ACS treatment Bryan Brewer – Washington, USA
	11:55 – 12:15	The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins J. Wouter Jukema – Leiden, The Netherlands
	12:15 – 12:45	The ApoC3 story: from basic science to metabolism to treatment Frank Sacks – Boston, USA

XCHANGE SESSION 19
THE ELDERLY PATIENT & CVD PREVENTION

Chairpersons: John Deanfield – London, UK / Coen Stehouwer – Maastricht, The Netherlands

	11:00 – 11:25	Family studies to unravel the missing heritability of CV risk - New approaches to genetic discovery Peter Nilsson – Lund, Sweden
	11:25 – 11:50	How are cardiovascular disease and dementia linked: A tale of two conditions Ruth Frikke Schmidt – Copenhagen, Denmark
	11:50 – 12:10	Clinical significance of arterial stiffening in diabetics and the elderly: Consequences for diagnostics and therapy? Coen Stehouwer – Maastricht, The Netherlands
	12:10 – 12:20	ABSTRACT 327 Eric Bruckert – Paris, France
	12:20 – 12:30	ABSTRACT 348 Inge van den Munckhof – Nijmegen, The Netherlands
	12:30 – 12:40	ABSTRACT 534 Wessel Fuijkschot – Amsterdam, The Netherlands
	12:40 – 12:45	DISCUSSION

XCHANGE SESSION 20.
CARDIOVASCULAR DISEASE IN CHRONIC KIDNEY DISEASE

Chairpersons: Dick de Zeeuw – Groningen, The Netherlands / Liffert Vogt – Amsterdam, The Netherlands

	11:00 – 11:25	The role of the angiotensin/Tie2 complex in the atherogenesis of chronic kidney disease Sascha David – Hannover, Germany
	11:25 – 11:45	The arterial glycocalyx, albuminuria and vascular damage in chronic kidney disease Ton Rabelink – Leiden, The Netherlands
	11:45 – 12:15	The role of dyslipidemia and its treatment in the prevention of nephron loss in CAD patients David Waters – San Francisco, USA
	12:15 – 12:25	ABSTRACT 116 Nestor Garcia – Cordoba, Argentina
	12:25 – 12:35	ABSTRACT 415 Uwe Querfeld – Berlin, Germany
	12:35 – 12:45	ABSTRACT 792 Liffert Vogt – Amsterdam, The Netherlands

11:00 – 12:45 **FHSC SESSION**

I-POSTER area **MODERATED POSTERS SESSION 3**

12:30	12:30 – 14:30	Therapy	●
	12:30 – 14:30	Cardiovascular Disease	●
14:30	12:30 – 14:30	Lowering lipids: The fat lady still didn't sing	●

INDUSTRY SPONSORED SYMPOSIUM

13:15 – 14:15 **Aegerion Pharmaceuticals** The lunchtime bulletin: Key facts and breaking news in homozygous familial hypercholesterolaemia (HoFH)

RAPID FIRE ARENA

13:15	13:15 – 14:15	RAPID FIRE SESSION 11: Dyslipidemia / genetics 2	●
14:15	13:15 – 14:15	RAPID FIRE SESSION 12: Biomarkers and imaging: Searching for the smoking gun or circumstantial evidence	●

POSTER area **POSTERS SESSION 6**

13:45	13:45 – 17:00	Therapy	●
	13:45 – 17:00	Glucose and lipids; Hypertension: Basic and clinical; Cardiac disease	●
	13:45 – 17:00	Epidemiology, imaging, prevention and guidelines	●
17:00	13:45 – 17:00	Therapy	●

X-CHANGE session

XCHANGE SESSION 21 ●●
INTERNATIONAL GUIDELINES UPDATE

Chairpersons: Željko Reiner – Zagreb, Croatia / Tamio Teramoto – Tokyo, Japan

14:45-15:15	The ACC-AHA 2013 US prevention guidelines: America leads the way? Neil Stone – Chicago, USA
15:15-15:40	The IAS guidelines: A more global view of intervention? Phil Barter – Sydney, Australia
15:40-16:05	The NLA guidance: A sharper view of the management of dyslipidemia? Matthew Ito – Portland, USA
16:05-16:30	A comparison of current guidelines: The good, the bad, and the uncertain Kausik Ray – London, UK

XCHANGE SESSION 22 ●
INNATE AND ADAPTIVE IMMUNITY IN ATHEROSCLEROSIS

Chairpersons: Johan Kuiper – Leiden, The Netherlands / Mihai Netea – Nijmegen, The Netherlands

14:45-15:10	The monocyte/macrophage as the key factor in the sequence between risk factor and unstable plaque Matthias Nahrendorf – Boston, USA
15:10-15:35	Defective inflammation resolution in atherosclerosis Ira Tabas – New York, USA
15:35-16:00	The role of B- and T-lymphocytes in inflammation and atherosclerosis Hafid Ait-Oufella – Paris, France
16:00-16:10	ABSTRACT 247 Jun-ichiro Koga – Fukuoka, Japan
16:10-16:20	ABSTRACT 664 Carrie Wiese – Nashville, USA

XCHANGE SESSION 23 ●
APOLIPOPROTEINS

Chairpersons: Jacqueline de Graaf – Nijmegen, The Netherlands / Alan Remaley – Bethesda, USA

14:45 – 15:15	Genetics and biology of apolipoproteins and enzymes involved in the regulation of ApoB containing lipoproteins Daniel Rader – Philadelphia, USA
15:15 – 15:45	Mutations in ApoA1 and their influence on CV risk: A – mis fit with the HDL hypothesis Ernst Schaefer – Boston, USA
15:45 – 16:10	Apo C-III as the new promotor of hypertriglyceridemia and CVD risk: From genetics to intervention Erik Stroes – Amsterdam, The Netherlands
16:10 – 16:30	LCAT mutations & CVD Laura Calabresi – Milan, Italy

XCHANGE SESSION 24 ●●
EVIDENCE-BASED LIFESTYLE INTERVENTIONS

Chairpersons: John Deanfield – London, UK / Coen Stehouwer – Maastricht, The Netherlands

14:45 – 15:10	How bad is smoking really: When and how did we acquire this evidence? Richard Peto – Oxford, UK
15:10 – 15:35	Can physical exercise and exercise mimetics improve metabolic health in humans? Patrick Schrauwen – Maastricht, The Netherlands
15:35 – 16:00	The Mediterranean diet: The ideal strategy to lower CVD risk? Emilio Ros – Barcelona, Spain
16:00 – 16:10	ABSTRACT 496 Peter J. Joris – Maastricht, The Netherlands
16:10 – 16:20	ABSTRACT 497 Kirsi Laitinen – Raisio, Finland
16:20 – 16:30	ABSTRACT 612 Nuria Amigo – Reus, Spain

14:45 – 16:30 **RUSSIAN SATELLITE SYMPOSIUM 2: Lipid studies in Russia: selected works**

CLINICAL BREAKTHROUGHS IN ATHEROSCLEROSIS

14:45-16:30 **CLINICAL BREAKTHROUGHS IN ATHEROSCLEROSIS SESSION 4: MODIFYING LIPIDS; RECENT DEVELOPMENTS** ●●

ISA-PLENARY session **PLENARY SESSION 6. STATIN THERAPY VERSUS NOVEL INTERVENTIONS: THE AGE OF DISCONTENT**

Chairpersons: J. Wouter Jukema – Leiden, The Netherlands / John Deanfield – London, UK

17:00	17:00 - 17:30	Statins Are Enough for the Prevention of CVD ●●	Kausik Ray – London, United Kingdom
18:00	17:30 - 18:00	Novel Interventions On Top of Statins Are Urgently Needed ●●	Ulrich Laufs – Homburg/Saar, Germany